F. Woltering
UCB
15 Papers
18 Citations
F. Woltering is an academic researcher from UCB. The author has contributed to research in topics: Certolizumab pegol & Medicine. The author has an hindex of 5, co-authored 9 publications.
Chat about Author
Papers
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
Philip J. Mease,Roy Fleischmann,A. Deodhar,Jürgen Wollenhaupt,Majed Khraishi,D. Kielar,F. Woltering,C. Stach,Bengt Hoepken,T. Arledge,D. van der Heijde +10 more
TL;DR: Rapid improvements in the signs and symptoms of PsA, including joints, skin, enthesitis, dactylitis and nail disease were observed across both CZP dosing regimens, independent of prior TNF inhibitor exposure.
493
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
D. van der Heijde,Roy Fleischmann,Jürgen Wollenhaupt,A. Deodhar,D. Kielar,F. Woltering,C. Stach,Bengt Hoepken,T. Arledge,Philip J. Mease +9 more
TL;DR: Inappropriate prespecified imputation methodology resulted in an unrealistic assessment of progression in all arms and demonstrated that CZP inhibited radiographic progression compared with placebo, particularly in patients with high baseline mTSS and C-reactive protein levels.
83
Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
TL;DR: The effects of certolizumab pegol (CZP) on PROs during the 24‐week, double‐blind phase of the RAPID axial spondyloarthritis trial, a phase 3 trial of axial SpA patients, including both ankylosing spONDylitis (AS) and nonradiographic axialSpA patients are evaluated.
36
Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study
10
Long-term Efficacy and Safety of Symptom-driven Cyclic Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis: A Pooled Analysis of a Phase 3 Study and Two Open-label Extension Studies (P1-5.012)
Vera Bril,Artur Druzdz,Julian Grosskreutz,Ali A. Habib,Renato Mantegazza,Kimiaki Utsugisawa,John Vissing,Tuan Vu,Mary Boehnlein,M. Gayfieva,Bernhard Greve,F. Woltering,Henry J. Kaminski +12 more
- 25 Apr 2023
TL;DR: For example, Bril et al. as mentioned in this paper evaluated the efficacy of cyclic rozanolixizumab treatment for generalized myasthenia gravis (MG-ADL, MGC and QMG scores.
3